Pfizer and its partner BioNTech submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate. The filing will potentially enable use of the vaccine in high-risk populations next month.
A new study highlights the need for stronger guidelines to manage the risk of osteoporosis and fractures in people with asthma who use steroid inhalers or pills.
No comments:
Post a Comment